CS-6 could inhibited osteosarcoma cells viability and tumorigenesis capability by blocking the TGF-βPI3K/AKT signaling pathway (Yuan et al., 2021; Ma et al., 2020), and its capacity to degrade c-Myc in multiple myeloma cells (Liu et al., 2017). The gene discussed is AKT1; the disease is plasma cell myeloma.